{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:20Z","timestamp":1760266400014,"version":"3.30.2"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6992,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1023\/a:1026551727795","type":"journal-article","created":{"date-parts":[[2003,11,6]],"date-time":"2003-11-06T17:11:16Z","timestamp":1068138676000},"page":"1405-1411","source":"Crossref","is-referenced-by-count":38,"title":["Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease"],"prefix":"10.1016","volume":"11","author":[{"given":"U.","family":"Axdorph","sequence":"first","affiliation":[]},{"given":"J.","family":"Sj\u00f6berg","sequence":"additional","affiliation":[]},{"given":"G.","family":"Grimfors","sequence":"additional","affiliation":[]},{"given":"O.","family":"Landgren","sequence":"additional","affiliation":[]},{"given":"A.","family":"Porwit-MacDonald","sequence":"additional","affiliation":[]},{"given":"M.","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1023\/A:1026551727795_bb0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/oxfordjournals.annonc.a059356","article-title":"Fixed versus response adapted MOPP\/ABVD chemotherapy in Hodgkin\u2019s disease","volume":"6","author":"BjSrkholm","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0065","series-title":"Hodgkin\u2019s Disease: The Consequences of Survival","first-page":"47","article-title":"Late effects of chemo-therapeutic agents","author":"Leyland-Jones","year":"1990"},{"key":"10.1023\/A:1026551727795_bb0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adulthood","volume":"18","author":"Van Leeuwen","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1026551727795_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: The relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1023\/A:1026551727795_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/annonc\/9.suppl_5.S63","article-title":"Radiotherapy in early stage Hodgkin\u2019s disease. Principles and results of recent clinical trials","volume":"9","author":"Noordijk","year":"1998","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1023\/A:1026551727795_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/9.suppl_5.S57","article-title":"The role of radiotherapy for early stage Hodgkin\u2019s disease: Limitations and perspectives","volume":"9","author":"Cosset","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0360-3016(97)00036-9","article-title":"Long-term outcome of treatment for Ann Arbor stage I Hodgkin\u2019s disease: Prognostic factors for survival and freedom from progression","volume":"38","author":"Vlachaki","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1023\/A:1026551727795_bb0095","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/oxfordjournals.annonc.a059009","article-title":"Treatment of early and intermediate stages of supradiaphragmatic Hodgkin\u2019s disease: The Swedish National Care Program experience","volume":"5","author":"Glimelius","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1600-0609.1978.tb02462.x","article-title":"Prognostic factors in Hodgkin\u2019s disease II. Role of the lymphocyte defect","volume":"20","author":"BjSrkholm","year":"1978","journal-title":"Scand J Haematol"},{"key":"10.1023\/A:1026551727795_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/bjc.1982.9","article-title":"Lymphocyte function in untreated Hodgkin\u2019s disease: An important predictor of prognosis","volume":"45","author":"Wedelin","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1026551727795_bb0110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-0142(19910815)68:4<768::AID-CNCR2820680418>3.0.CO;2-1","article-title":"Lymphocyte abnormalities predicting a poor prognosis in Hodgkin\u2019s disease","volume":"68","author":"Tullgren","year":"1991","journal-title":"Cancer"},{"key":"10.1023\/A:1026551727795_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00402504","article-title":"Acute phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin\u2019s disease","volume":"110","author":"Zielinski","year":"1985","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1023\/A:1026551727795_bb0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.1992.tb08895.x","article-title":"Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of poor prognosis in adult Hodgkin\u2019s disease","volume":"80","author":"Grimfors","year":"1992","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1023\/A:1026551727795_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/3.suppl_4.S49","article-title":"Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin\u2019s lymphoma","volume":"3","author":"Gause","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/oxfordjournals.annonc.a059044","article-title":"Serum levels of interleukin-2 receptor (CD25) in patients with Hodgkin\u2019s disease, with special reference to age and prognosis","volume":"6","author":"Enblad","year":"1995","journal-title":"Ann Oncol"},{"year":"1996","series-title":"Serum levels of soluble Interleukin-2 receptor (sCD25) are increased in untreated patients with Hodgkin\u2019s disease with impaired blood lymphocyte function and a poor prognosis. Second meeting of the European Haematology Association","author":"Axdorph","key":"10.1023\/A:1026551727795_bb0135"},{"key":"10.1023\/A:1026551727795_bb0140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/bjc.1998.163","article-title":"Soluble interleukin-2 receptors (sIL-2R) in Hodgkin\u2019s disease: Outcome and clinical implications","volume":"77","author":"Viviani","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1026551727795_bb0145","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V91.8.3011.3011_3011_3016","article-title":"Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin\u2019s disease at high risk of unfavorable outcome","volume":"91","author":"Nadali","year":"1998","journal-title":"Blood"},{"key":"10.1023\/A:1026551727795_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428199509107894","article-title":"Soluble ICAM-1 in Hodgkin\u2019s disease: A promising independent predictive marker for survival","volume":"19","author":"Christiansen","year":"1995","journal-title":"Leuk Lymph"},{"year":"1995","series-title":"Serum levels of sICAM-1 are correlated to tumour burden and blood lymphocyte functions in untreated Hodgkin\u2019s disease. Third International Symposium on Hodgkin\u2019s Lymphoma","author":"Axdorph","key":"10.1023\/A:1026551727795_bb0155"},{"key":"10.1023\/A:1026551727795_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008301602785","article-title":"Interleukin-10 levels are often elevated in serum of adults with Hodgkin\u2019s disease and are associated with inferior failure-free survival","volume":"10","author":"Sarris","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0165","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.1993.11.6.1108","article-title":"Prognostic role of serum \u03b22-microglobulin in Hodgkin\u2019s disease","volume":"11","author":"Dimopoulos","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1026551727795_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/02841868509134381","article-title":"Serum thymidine kinase as a prognostic marker in Hodgkin\u2019s disease","volume":"24","author":"Eriksson","year":"1985","journal-title":"Acta Radiol Oncol"},{"key":"10.1023\/A:1026551727795_bb0175","first-page":"2118","article-title":"Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin\u2019s disease and with B symptoms","volume":"53","author":"Kurzrock","year":"1993","journal-title":"Cancer Res"},{"key":"10.1023\/A:1026551727795_bb0180","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/bjc.1998.391","article-title":"Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin\u2019s disease patients","volume":"77","author":"Warzocha","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1026551727795_bb0185","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1026551727795_bb0190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/A:1008325627670","article-title":"Is the international prognostic score for advanced stage Hodgkin\u2019s disease applicable to early stage patients?","volume":"11","author":"Franklin","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1026551727795_bb0195","series-title":"Hodgkin\u2019s Disease","first-page":"295","article-title":"Prognostic factors of Hodgkin\u2019s disease","author":"Specht","year":"1999"},{"key":"10.1023\/A:1026551727795_bb0200","series-title":"Important Advances in Oncology","first-page":"111","article-title":"A practical approach to the pathology of lymphoid neoplasms: A revised European\u2013American classification from the international lymphoma study group","author":"Harris","year":"1995"},{"key":"10.1023\/A:1026551727795_bb0205","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I","article-title":"Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin\u2019s disease","volume":"64","author":"MacLennan","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1026551727795_bb0210","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1023\/A:1026551727795_bb0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.1977.tb01505.x","article-title":"Prognostic factors in Hodgkin\u2019s disease. I. Analysis of histopathology, stage distribution and results of therapy","volume":"19","author":"Bjorkholm","year":"1977","journal-title":"Scand J Haematol"},{"key":"10.1023\/A:1026551727795_bb0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.0954-6820.1986.tb03318.x","article-title":"Prognostic influence of early diagnostic splenectomy in Hodgkin\u2019s disease. A long-term follow-up","volume":"219","author":"Askergren","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1023\/A:1026551727795_bb0225","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Soc"},{"key":"10.1023\/A:1026551727795_bb0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/biomet\/52.1-2.203","article-title":"A generalised Wilcoxon test for comparing arbitrarily single-censored samples","volume":"52","author":"Gehan","year":"1965","journal-title":"Biometrika"},{"key":"10.1023\/A:1026551727795_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"B34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1023\/A:1026551727795_bb0240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s002770050564","article-title":"Poor clinical outcome of patients with Hodgkin\u2019s disease and elevated interleukin-10 serum levels","volume":"79","author":"Bohlen","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1023\/A:1026551727795_bb0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02826218","article-title":"Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin\u2019s disease, the Milan Cancer Institute Experience","volume":"17","author":"Viviani","year":"2000","journal-title":"Med Oncol"},{"key":"10.1023\/A:1026551727795_bb0250","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJM199904223401615","article-title":"Prognostic score for Hodgkin\u2019s disease","volume":"340","author":"Jack","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/11\/1405\/19477949\/11-11-1405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T08:45:16Z","timestamp":1734165916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419557027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S0923753419557027"],"URL":"https:\/\/doi.org\/10.1023\/a:1026551727795","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}